AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q1 2014 Earnings Presentation

27 slides from AMAG Pharmaceuticals's earnings presentation, Apr 24, 2014

  1. Slide 1: AMAG Pharmaceuticals First Quarter 2014 Financial Results

    AMAG Pharmaceuticals First Quarter 2014 Financial Results April 24, 2014 AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES. Copyright 2014 AMAG Phar

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements 1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, state

  3. Slide 3: Agenda

    Agenda 2 Topic Speaker Opening Remarks Bill Heiden, CEO Commercial Performance Ed Jordan, SVP Sales & Marketing Expansion Opportunities Bill Heiden, CEO Financial Highlights & Outlook Frank Thomas, COO Closing Remarks Bill Heiden, CEO

  4. Slide 4: Mission: Build a Profitable, Multi-product Specialty Pharmaceutical Company

    Mission: Build a Profitable, Multi-product Specialty Pharmaceutical Company Commercial Infrastructure Focus on Hematology/Oncology, Hospital and Nephrology Strong Balance Sheet Experienced Management Team Feraheme® U.S. CKD Business Feraheme IDA label Expansion* IV Iron Market Expansion Feraheme Geo

  5. Slide 5: First Quarter 2014 Highlights

    First Quarter 2014 Highlights 4 Strong 1Q14 financial performance vs 1Q13 17% increase in total revenue 12% increase in U.S. Feraheme ex-factory net sales Voulme and net revenue per gram growth Expenses in-line with financial guidance Robust physician-level demand growth vs 1Q13 17% Feraheme volume

  6. Slide 6: Feraheme Performance

    FERAHEME PERFORMANCE Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved.

  7. Slide 7: Overall Feraheme Demand Growth

    Overall Feraheme Demand Growth 6 Source: IMS Health Data. *Evolution Index = Product Growth Divided by Market Growth Evolution Index* (E.I.) of 110 Growing 10% faster than the market in 1Q14 vs. 1Q13; taking share from the competition

  8. Slide 8: Feraheme Demand Growth by Segment

    Feraheme Demand Growth by Segment 7 Market Share & E.I. 1Q14 vs 1Q13 Total non-dialysis IV iron market 15.5% market share; E.I. 110 Hospital segment 10% market share; E.I. 114 Hem/Onc segment 26% market share; E.I. 100 Source: IMS Health Data.

  9. Slide 9: Competitive Landscape: U.S. IV Iron Market

    Competitive Landscape U.S. IV Iron Market ~850,000 Grams Annually 8 *Aggregate of Ferrlecit Brand + Generic Ferric Gluconate 1Q14 Share of Non-dialysis Market (Grams) Venofer Iron Dextran / Dexferrum Injectafer * Ferric Gluconate 15.5% (vs. 14.2% in 1Q13) Source: IMS Health Data. 15.2% 44.1% 3.9% 21

  10. Slide 10: Today's Commercial Objective: Increase Share of Current CKD IV Iron Market

    Today’s Commercial Objective: Increase Share of Current CKD IV Iron Market 9 Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes an

  11. Slide 11: MuGard Performance

    ~ MUGARD PERFORMANCE

  12. Slide 12: MuGard: >$500 Million Market Opportunity

    MuGard: >$500 Million Market Opportunity Prescription oral rinse for the management of oral mucositis (OM) Only OM product that forms a protective coating over the oral mucosa to shield the membranes of the mouth and tongue Incremental medical care cost of severe OM in head and neck cancer patients

  13. Slide 13: Two Key Levers for MuGard's Success in 2014

    12 MuGard for the management of oral mucositis Two key levers for MuGard’s Success in 2014 Increase Rx’s into MuGard Hub 2) Increasing Payer Coverage MuGard Specialty Pharmacy Hub (reimb verification, co-pay asst., & product distribution) MuGard sales Effective physician Targeting Differentiate MuGa

  14. Slide 14: Expansion Opportunities

    EXPANSION OPPORTUNITIES Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved.

  15. Slide 15: Potential IDA Label Expansion: Gain Additional Share of IV Iron Market

    14 Sources: U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010: 41-42; Fishbane, S. e

  16. Slide 16: Opportunity: Grow U.S. IV Iron Market

    Opportunity: Grow U.S. IV Iron Market 15 IV Iron IDA* IV Iron IDA-CKD 4,000,000 patients diagnosed with IDA placed on oral iron therapy IV Iron IDA-CKD IV Iron IDA* Oral Iron IDA* Oral Iron IDA-CKD *If regulatory approval is pursued and received. 4,000,000 patients diagnosed with IDA placed on oral

  17. Slide 17: Regulatory Update: Feraheme & Rienso

    Regulatory Update: Feraheme & Rienso 16 Feraheme U.S. Broad IDA Label Evaluating FDA complete response letter Developing responsive and economically viable proposal 2Q14 Expected FDA end of review meeting for sNDA 2H14 - Determination of path forward and impelmentation Rienso EMA Broad IDA Label CHM

  18. Slide 18: Targeted Business Development

    Targeted Business Development 17 Financial Similarly sized specialty company Eliminate overlapping infrastructure and increase EBITDA Examine transactions to optimize after-tax cash flows ~ 75 small private companies with U.S. marketed specialty products Strategic Opportunities aligned with Feraheme

  19. Slide 19: Examples of Successfully Executing a Build Strategy

    Examples of Successfully Executing a Build Strategy 18 Industry peers have utilized business development to broaden their portfolios and reduce dependence on a single commercial product Oritavancin FibroCapsTM IONSYSTM Cangrelor

  20. Slide 20: Financial Highlights & Outlook

    FINANCIAL HIGHLIGHTS & OUTLOOK Copyright © 2014 AMAG Pharmaceuticals, Inc. All Rights Reserved.

  21. Slide 21: Feraheme Ex-Factory Sales Performance

    Feraheme Ex-Factory Sales Performance 20 Ex-factory net sales* ($ in millions) * Excludes the impact of changes in estimates made to product returns and Medicaid reserves in 2012 and 2013 1Q14 vs 1Q13 +12% growth (+7% volume, +5% price)

  22. Slide 22: First Quarter Financial Highlights

    First Quarter Financial Highlights ($ in millions, except per share) 1Q13 1Q14 U.S. Feraheme net sales $15.6 $17.4 Total revenues $17.9 $20.8 Feraheme gross margin $12.9 $14.8 R&D expenses $5.4 $6.5 SG&A expenses $14.0 $17.5 Net loss $(3.9) $(7.1) Net loss per share $(0.18) $(0.33) Cash and investme

  23. Slide 23: 2014 Financial Outlook

    2014 Financial Outlook ($ in millions) 2014 Projections* Change from 2013 (calculated at midpoint of 2014 range)* Total revenues $88 - $100 +16% U.S. Feraheme net sales $75 - $85 +12% Feraheme COGS (% of Feraheme global net sales) 14% - 16% -12% Operating expenses $80 - $85 +3% Net loss ($10 - $12)

  24. Slide 24: Key Financial Metrics: Positive Trends 2011 - 2014

    Key Financial Metrics: Positive Trends 2011 - 2014 23 Revenues ($ in millions) Expenses ($ in millions) Copyright 2014 AMAG Pharmaceuticals, Inc. All Right Reserved.

  25. Slide 25: 2014 Goals

    2014 Goals Maximize Feraheme opportunities Drive market share and market growth within current U.S. IDA-CKD indication Optimize net revenue per gram Potential label expansion: broad IDA Determine regulatory path forward in U.S. Expected EU action – 3Q14; broad IDA approval triggers significant miles

  26. Slide 26: Well positioned for success in 2014... and beyond

    Well positioned for success in 2014. . . and beyond. AMAG Pharmaceuticals, Inc. 1100 Winter Street Waltham, MA 02451 617.498.3300 www.amagpharma.com A SPECIALTY PHARMACEUTICAL COMPANY DEDICATED TO BRINGING TO MARKET THERAPIES THAT IMPROVE PATIENTS’ LIVES. Copyright 2014 AMAG Pharmaceuticals, Inc. Al

  27. Slide 27: Adjusted EBITDA Reconciliation

    Adjusted EBITDA Reconciliation 26 ($ in millions) 2013 2014 (est.) Net loss ($9.6) ($10 - $12) Interest expense and amortization of debt discount and deferred financing costs $ - $10 - $12 Sub-total ($9.6) $ - Depreciation & amortization $3.1 $1 - $2 Interest income ($1.1) ($1 - $2) EBITDA ($7.6) ($

AMAG Pharmaceuticals — Q1 2014 Earnings Presentation on 6ix